Abstract The pituitary adenylate cyclase-activating polypeptide (PACAP) increases excitability of guinea pig cardiac neurons, an effect mediated through activation of PAC 1 receptors. The signaling cascades that couple activation of the PAC 1 receptor to alterations in membrane ionic conductances responsible for the PACAP effect are unknown. Intracellular recordings were made from neurons in kinase inhibitor-treated cardiac ganglia preparations to determine which of the intracellular cascades activated by PAC 1 receptor stimulation mediate the PACAP effect. In control cells, long depolarizing-current steps elicited one to three action potentials. In contrast, during the application of 10 nM PACAP, depolarizing-current pulses elicited multiple action potential firing (greater than or equal to five action potentials) in 79% of the neurons. Pretreatment with an adenylyl cyclase inhibitor, SQ 22536 (100 µM), suppressed the PACAP-induced increase in excitability, whereas the presence of U-73122 (10 µM), a potent phospholipase C (PLC) inhibitor, had no effect. Thus, the activation of adenylyl cyclase, but not PLC, was a critical step mediating the PACAP effect. Pretreatment with H-89 (1 µM), a protein kinase A inhibitor, and PD 98059 (50 µM), a MEK kinase inhibitor, also significantly blunted the PACAP-induced increase in excitability. Furthermore, treatment with forskolin (5 µM), an activator of adenylyl cyclase, or exposure to the cell-permeable cyclic adenosine monophosphate (cAMP) analogue, 8-bromo-cAMP (1 mM), partially recapitulated the effect of PACAP on excitability. We conclude that the activation of signaling cascades downstream of cAMP mediate the PACAPinduced increase in cardiac neuron excitability.
Introduction
In the guinea pig, pituitary adenylate cyclase-activating polypeptide (PACAP) is present in the cholinergic preganglionic parasympathetic terminals innervating all neurons in the intrinsic cardiac ganglia (Braas et al. 1998; Calupca et al. 2000; Parsons et al. 2006 ). In addition, virtually all guinea pig intrinsic cardiac neurons express the PACAPselective PAC 1 receptor, and the application of PACAP to these neurons dramatically increases neuronal excitability (Braas et al. 1998; Tompkins et al. 2006) . Most guinea pig cardiac neurons are phasic, initiating only an initial burst of one to three action potentials in response to long-duration, suprathreshold depolarizing-current pulses (Hardwick et al. 1995; Adams and Cuevas 2004) . However, following PACAP application, the neuronal response often becomes more "tonic-like" such that multiple action potentials are initiated throughout the depolarization elicited by comparable stimuli (Braas et al. 1998; Tompkins et al. 2006 ). The specific PAC 1 receptor agonist maxidilan mimics the effect of PACAP on excitability, whereas the closely associated peptide vasointestinal polypeptide does not (Braas et al. 1998; Tompkins and Parsons, unpublished observations) . These observations indicate that the increase in excitability of guinea pig cardiac neurons by PACAP is mediated solely through the activation of PAC 1 receptors. However, the mechanisms underlying the PAC 1 receptor-mediated increase in excitability are unknown. PAC 1 receptors are members of the superfamily of seven transmembrane G-protein coupled receptors and commonly activate the adenylyl cyclase and phospholipase C (PLC) intracellular signaling pathways (Braas and May 1999; Vaudry et al. 2000) . We reasoned that if a PACAP-induced activation of the adenylyl cyclase or PLC intracellular signaling cascades mediated the PACAPinduced increase in excitability, then treatment with inhibitors of these intracellular transduction pathways should blunt the PACAP effect on excitability. Thus, in the present study, we tested whether well-established inhibitors of adenylyl cyclase and PLC suppressed the PACAPinduced increase in excitability. Our results demonstrate that activation of adenylyl cyclase is a critical mechanism underlying the PACAP-induced increase in excitability. In contrast, the PACAP-induced increase in excitability remained in the presence of a potent PLC inhibitor. The PACAP-induced increase in excitability also was suppressed in preparations treated with either H-89, a potent protein kinase A (PKA) inhibitor, or PD 98059, a MEK kinase inhibitor, suggesting that the activation of these kinases also was required for the PACAP-induced increase in excitability in some cardiac neurons. It is interesting to note that forskolin, a potent activator of adenylyl cyclase, and 8-bromo cyclic adenosine monophosphate (cAMP), a cell-permeable cAMP analogue, only partially mimicked the PACAP-induced increase in excitability, suggesting that other mechanisms, along with a rise in cAMP and activation of additional downstream signaling cascades, must also be involved in the PACAP-induced increase in excitability.
Materials and Methods

General Methods
Experiments were performed in vitro on atrial wholemount preparations containing the intrinsic cardiac ganglia from Hartley guinea pigs (either sex; 250-350 g) as described previously (Tompkins et al. 2006; Tompkins et al. 2007 ). Guinea pigs were killed by halothane or isoflurane overdose followed by exsanguination using animal protocols approved by the University of Vermont Institutional Animal Care and Use Committee and methods described in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize the number of animals used and their suffering. The heart was quickly removed and placed in cold standard Krebs solution (in mM: 121 NaCl, 5.9 KCl, 2.5 CaCl 2 , 1.2 MgCl 2 , 25 NaHCO 3 , 1.2 NaH 2 PO 4 , 8 glucose). The pH was maintained at 7.4 by aeration with 95% O 2 -5% CO 2 .
Intracellular Recordings from Neurons in Whole-mount Preparations
For intracellular recordings, atrial whole-mount preparations were pinned in a 2.5-ml Sylgard-lined chamber and superfused continuously (2-3 ml/min) with a modified Krebs solution containing 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer (33-35°C; Hardwick et al. 1995; Hardwick et al. 1997; Braas et al. 1998; Tompkins et al. 2006; Tompkins et al. 2007 ). Cardiac ganglia were visualized with an inverted microscope equipped with Hoffman optics, and individual cardiac neurons were impaled using high-impedance borosilicate microelectrodes (2 M KCl-filled; 60-100 MΩ). Resting membrane potential and action potentials were recorded from the impaled neurons using an Axoclamp-2A amplifier coupled with a Digidata 1322A data acquisition system and pCLAMP 8 (Axon Instruments, Foster City, CA, USA). If required, a hyperpolarizing current was injected through the recording electrode to electrotonically maintain the resting membrane potential between −55 and −65 mV. This ensured that action potential generation was tested at the same potential prior to and following PACAP application (Tompkins et al. 2006 ).
Depolarizing-current steps (0.1-0.4 nA, 1 s) were given to characterize changes in neuron excitability before and after drug application. If the number of action potentials generated during the supratheshold depolarizing steps was 4 or less, then the cell was classified as "phasic." However, if the number of action potentials elicited was 5 or more, then the action potential firing pattern was considered "multiple firing." Excitability curves were constructed by plotting the number of action potentials generated by increasing stimulus intensities. Results were averaged from multiple cells under each condition and fit with a straight line. The slope of the regression line was used to compare neuronal excitability between cells studied under different conditions.
Drugs
All drugs were made up as stock solutions, and aliquots were added directly to the bathing solution. Because PACAP27 was determined previously to be more effective than PACAP38 on guinea pig cardiac neurons (Braas et al. 1998; Braas et al. 2004) , it was used exclusively in this study and is referred to as PACAP throughout the text. All drugs were obtained from commercial sources: PACAP27 was obtained from American Peptide (Sunnyvale, CA, USA) and forskolin, 8-bromo-cAMP, 2′-amino-3′-methoxyflavone (PD 98059), 9-(tetrahydro-2′-furyl)adenine (SQ 22536) , and N-[2-((p-Bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide (H-89) were obtained from Calbiochem (La Jolla, CA, USA). Forskolin, H-89, PD 98059, SQ 22536, and U-73122 were made up in dimethylsulfoxide (0.3% final concentration).
Statistical Evaluation
Best-fit linear regression lines were calculated and compared between groups using GraphPad Prism (V3) statistical software (San Diego, CA, USA). Differences were considered statistically significant if P<0.05.
Results
Cardiac Neuron Excitability is Enhanced During Bath Application of 10 nM PACAP
In the initial experiments, the effect on excitability of adding 10 nM PACAP directly to the bath was established. Excitability was determined from the response to 1-s depolarizingcurrent pulses of increasing amplitude (Tompkins et al. 2006; Tompkins et al. 2007 ). In the present study, recordings were made from 23 control guinea pig cardiac neurons, each from an independent whole-mount preparation. All 23 were considered phasic cells based on the criteria described in "Materials and Methods." In 21 control cells, the maximum number of action potentials elicited by any stimulus was 2. The remaining two cells generated a maximum of three action potentials. In contrast, during bath exposure to 10 nM PACAP, multiple action potentials were generated by the same depolarizing steps in 79% of the cells (Fig. 1a) . In five cardiac ganglia preparations exposed to PACAP over a recording period of 120 min, 11 of 14 cells produced greater than or equal to five action potentials in response to suprathreshold voltage steps (Fig. 1b) . The average excitability curve for cells exposed to PACAP is shown in Fig. 2 .
Pretreatment with the Adenylyl Cyclase Inhibitor SQ 22536 but not the PLC Inhibitor U-73122 Blocked the PACAPinduced Increase in Cardiac Neuron Excitability As PAC 1 receptors often are coupled to both adenylyl cyclase and PLC (Braas and May 1999) , the initial experiments tested whether the presence of established inhibitors of either intracellular signaling pathway suppressed the PACAP effect on excitability. To test the potential role of PLC in the PACAP effect, recordings were made from ten neurons in three cardiac ganglia preparations treated with 10 µM U-73122. In each preparation, excitability was first determined in one cell treated for 20 min with U-73122 alone, and then the same cell was tested after exposure to both U-73122 and 10 nM PACAP for 5-10 min. All three cells exposed to U-73122 alone exhibited a phasic firing pattern in response to longduration depolarizing-current pulses. However, during exposure to PACAP, the firing pattern shifted from a phasic to a multiple firing pattern in two of the three cells within 10 min. Recordings were then made from seven other neurons in these three preparations for times up to 120 min in the continued presence of U-73122 and PACAP. In all, seven of ten neurons sampled during the 120-min exposure to PACAP and U-73122 exhibited multiple action potential firing (Fig. 3) . The excitability curve determined for these ten cells in PACAP and U-73122 (slope=20.90±1.4) was not different from that determined for cells exposed just to PACAP (slope=18.14±1.1, P=0.17; Fig. 2 ). These observations indicated that the activation of PLC was not required for the PACAP-induced increase in excitability. To test whether the PACAP-induced increase in excitability required activation of adenylyl cyclase, three preparations were exposed to 100 μM SQ 22536 for at least 20 min before adding 10 nM PACAP to the bath solution. Excitability was tested in three cells (one from each preparation) exposed to only SQ 22536, and then excitability was tested in the same cells 5-10 min after switching to a bath solution containing SQ 22536 and 10 nM PACAP. The three cells treated only with SQ 22536 were phasic and remained phasic after exposure to 10 nM PACAP. Four additional cells from these three preparations were sampled at different times over a 120-min recording period in a solution containing PACAP and SQ 22536. Only one of these four cells exhibited multiple action potential firing, and the other three exhibited a phasic firing pattern. The excitability curve determined for the seven cells exposed to PACAP and SQ 22536 is shown in Fig. 2  (slope=7.14±1.3) . The presence of SQ 22536 significantly suppressed the PACAP-induced increase in excitability (P= 0.0006, Figs. 2 and 3) .
Activation of adenylyl cyclase increases cAMP production and the rise in cAMP can activate PKA. Phosphorylation by PKA of proteins regulating surface membrane ionic conductances might be a mechanism downstream of cAMP generation involved in the PACAP modulation of excitability. To test this possibility, the ability of 10 nM PACAP to increase excitability was determined in three preparations pretreated with 1 µM H-89, a commonly used PKA inhibitor. As in the previous experiments, recordings were obtained from one cell in each preparation pretreated with only H-89 and then from the same cell 5-10 min after exposure to PACAP along with H-89. In three cells exposed for greater than 15 min to H-89 alone, the firing pattern was phasic. In one of these three cells, the firing pattern was converted to "multiple firing" during exposure to PACAP. In the other two cells, the firing pattern in the presence of PACAP remained phasic. Recordings were then obtained from ten other cells in these three preparations exposed for 120 min to 1 µM H-89 and 10 nM PACAP. In all, 10 of 13 cells retained a phasic firing pattern, whereas only three exhibited a multiple action potential firing pattern (Fig. 3) . Thus, treatment with H-89 markedly reduced the PACAP-induced increase in excitability. The averaged excitability curve for the cells treated with PACAP and H-89 is shown in Fig. 4 . Note that for cells treated with H-89 and PACAP, the slope of the averaged excitability curve was significantly less than that determined for cells exposed to only PACAP (8.85±0.8 vs 18.14±1.1, P=0.0004).
Pretreatment with the MEK Kinase Inhibitor PD 98059 also Suppressed the PACAP-induced Increase in Cardiac Neuron Excitability
In prior studies, we noted that the mitogen-activated protein kinase (MAPK) kinase pathway contributed to the initiation 
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% multiple firing cells ( ≥ 5 APs) (9) (10) Figure 2 Adenylyl cyclase inhibition reduces the PACAP effect on excitability. Excitability curves summarizing the effects of the adenylyl cyclase inhibitor SQ 22536 and the PLC inhibitor U-74122 on the PACAP-induced changes in neuronal firing. SQ 22536 significantly blunted the PACAP effect on neuronal excitability, while the presence of U-73122 had no effect. Data are plotted as the mean number of action potentials generated with a 1-s depolarizing current pulse at multiple stimulus intensities. Data points for each treatment (error bars show SEM) were fit by linear regression, and the difference in slope between treatments was analyzed. Treatments were done separately in multiple preparations of other PACAP actions on the guinea pig cardiac neurons (Braas et al. 2004) . Thus, we also tested whether the treatment with the MEK kinase inhibitor PD 98059 (50 µM), to disrupt the MAPK signaling cascade, diminished the ability of PACAP to increase cardiac neuron excitability. The effect of PD 98059 was studied in three preparations. Recordings were obtained from one cell in each of the three preparations during exposure to the inhibitor alone and then following exposure to PD 98059 and PACAP. Excitability was tested with depolarizingcurrent steps of increasing intensity. All three cells exhibited a phasic firing pattern when exposed to PD 98059 alone. The same three cells continued to exhibit a phasic firing pattern after a 10-min exposure to the inhibitor and PACAP. The firing pattern was tested in six other cells during continued exposure to the inhibitor and PACAP. Over the 120-min recording period in the inhibitor and PACAP, only one of the six cells sampled exhibited multiple action potential firing during the depolarizingcurrent steps. The other four cells remained phasic. Thus, in the presence of the MEK kinase inhibitor, only one of nine PACAP-treated cells generated multiple action potentials (Fig. 3) . The averaged excitability curve for the nine cells treated with PACAP and PD 98059 is summarized in Fig. 4 . From inspection of the results in Fig. 4 , it is evident that the slope of the excitability curve for these cells was significantly less than that determined for the 14 cells exposed to PACAP alone (4.89±0.6 vs 18.14±1.1, P<0.0001).
The Potent Adenylyl Cyclase Activator Forskolin and the Cell Permeable cAMP Analogue 8-bromo-cAMP only Partially Mimic the PACAP-induced Increase in Excitability
The suppression of the PACAP effect on excitability by SQ 22536 indicated that activation of adenylyl cyclase and generation of cAMP was a key first step in the peptideinduced increase in excitability. Additional experiments tested whether a rise in cAMP by itself could duplicate the effects of PACAP on excitability. For these experiments, we tested whether the bath application of 5 µM forskolin, a potent activator of adenylyl cyclase, or exposure to 1 mM 8-bromo-cAMP, a cell membrane-permeable cAMP analogue, could produce a comparable increase in cardiac neuron excitability. Ten cells from four cardiac ganglia preparations were exposed to forskolin, and nine cells from three preparations were exposed to 8-bromo-cAMP. With either treatment, only 30-33% of the cells tested exhibited a multiple firing pattern in response to the depolarizing current steps; the remainder exhibited a phasic firing pattern, throughout the 120-min recording period (Fig. 3) . The averaged excitability curve for the cells exposed either to forskolin or to 8-bromo-cAMP is shown in Fig. 5 . The slope of the excitability curve for cells exposed to forskolin (7.40±0.4) or 8-bromo-cAMP (10.44±1.2) was significantly less than that for cells exposed to PACAP (P< 0.0001 and P=0.003, respectively). Thus, a rise in cAMP by itself could only partially recapitulate the PACAP effect on excitability. 
Discussion
In the present study, we determined the percentage of cells that exhibited a phasic or multiple action potential firing pattern to establish whether interruption of different intracellular signaling cascades affected the PACAP-induced increase in excitability.
In many cell types, the PAC 1 receptor can activate both PLC and adenylyl cyclase (Braas and May 1999; Vaudry et al. 2000) . Treatment with the adenylyl cyclase inhibitor SQ 22536 significantly suppressed the PACAP-induced increase in excitability. However, the PACAP modulation of cardiac neuron excitability remained after the treatment with a well-established PLC inhibitor. Thus, the key result from this study is that the PACAP-induced increase in cardiac neuron excitability required the activation of adenylyl cyclase but not PLC. Our data indicating a lack of involvement of PLC in the effect of PACAP on guinea pig cardiac neuron excitability confirms preliminary observations reported previously (Parsons 2004) .
We found that during bath application of 10 nM PACAP, excitability was increased in 79% of the cardiac neurons using the criterion that five or more action potentials were initiated during the depolarizing current steps. Under the conditions of the present experiments, we anticipated that a small percentage of cardiac neurons would not be affected by PACAP as results from our previous study indicated that the EC50 for the PACAP-induced increase in excitability was~20 nM (Braas et al. 1998 ). In addition,~10% of the guinea pig cardiac neurons in untreated preparations are tonic so that during long depolarizing pulses, multiple action potentials are elicited (Hardwick et al. 1995; Adams and Cuevas 2004) . Therefore, it would be expected that in any drug-treated group of cells, occasionally, a cardiac neuron might exhibit a tonic firing pattern even if the action of PACAP was blocked. Thus, we suggest the one cell that exhibited a multiple firing pattern during exposure to PACAP and SQ 22536, as well as with PACAP and PD 98059, very likely was a tonic neuron rather than a phasic cell, which had been converted to a multiple firing pattern by PACAP.
In H-89-treated ganglia, PACAP increased excitability in only a small percentage of the cardiac neurons. H-89 is commonly used to inhibit PKA. Thus, our results are consistent with the activation of PKA by cAMP as a key step supporting the PACAP effect on excitability. However, the results with H-89 must be interpreted carefully. First, H-89 is not selective as it can inhibit a number of protein kinases in addition to PKA with a similar EC50 (Davies et al. 2000) . Second, in initial experiments, we tested excitability in cardiac neurons exposed to higher H-89 concentrations (5 and 10 μM). When exposed to H-89 in this concentration range for more than a few minutes, most cardiac neurons had low resting membrane potentials, and even when the membrane potential was electrotonically returned to −50 to −60 mV, values close to the resting membrane potential in control cells, action potential generation was compromised. In addition, when action potentials were generated, they had a reduced amplitude and were broadened. Thus, H-89 at the concentrations commonly used in cell studies (10-25 μM) apparently affected some basic electrical properties of the guinea pig cardiac neurons. Taken together, we suggest further study with other PKA inhibitors is required before the role of PKA can be established unequivocally.
Previously, Merriam et al. (2004) demonstrated, using dissociated guineas pig cardiac neurons, that PACAP enhanced the hyperpolarization-activated, cyclic nucleotide-gated nonselective cationic conductance I h . Forskolin had a similar effect. Thus, it was concluded that the effect of PACAP on I h was mediated through the activation of adenylyl cyclase and generation of cAMP. As I h is a pacemaker current known to facilitate multiple action potential firing, it is very plausible that one mechanism contributing to the PACAP-induced increase in excitability is an activation of adenylyl cyclase and generation of cAMP, which then shifts the voltage dependence of activation of I h to more positive potentials. However, I h is present in only a subset of the guinea pig cardiac neurons (Edwards et al. 1995) . Thus, although a PACAP-enhanced I h could be a mechanism contributing to the change in excitability in some cardiac neurons, other ionic mechanisms must contribute to the enhanced excitability in cells not expressing I h .
In addition to the canonical cAMP-PKA transduction pathway, there is a noncanonical pathway for cAMPmediated effects, which involves cAMP activation of exchange protein activated by cAMP and subsequent activation of other intracellular cascades including the MAPK signaling pathway (Gerdin and Eiden 2007) . The MEK kinase inhibitor, PD 98059, significantly suppressed the PACAP-induced increase in excitability. This suggests that a PAC 1 receptor activation of the MAPK intracellular signaling pathway also was a key pathway mediating the PACAP effect. The specific ionic conductances, which might be affected by a PACAP-induced activation of MAPK intracellular signaling remain to be determined, a question to be the subject of future studies.
Although pretreatment with an adenylyl cyclase inhibitor greatly suppressed the PACAP effect, the activation of adenylyl cyclase by forskolin or application of the cell membrane-permeable cAMP analogue 8-bromo-cAMP only increased excitability in a limited percentage of the cardiac neurons. Thus, other mechanisms in addition to the activation of adenylyl cyclase and generation of cAMP must be critical cofactors in mediating the PACAP-induced increase in cardiac neuron excitability. Previously, we determined that Ca 2+ influx through an unidentified plasma membrane ion channel was a requisite for the PACAP-induced increase in excitability (Tompkins et al. 2006) . Thus, we propose that both a rise in cAMP and Ca 2+ are critical mechanisms in the initiation of the PACAPinduced increase in cardiac neuron excitability.
